Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr;170(6):774-777.
doi: 10.1007/s10517-021-05152-0. Epub 2021 Apr 24.

Choice of Tactics for Experimental Therapy of Chronic Heart Failure with ALM-802 Compound

V V Barchukov  1 , I B Tsorin  1 , M B Vititnova  1 , A O Efimova  1 , A M Likhosherstov  1 , G V Mokrov  1 , S A Kryzhanovskii  2
Affiliations

Choice of Tactics for Experimental Therapy of Chronic Heart Failure with ALM-802 Compound

V V Barchukov et al. Bull Exp Biol Med. 2021 Apr.

Abstract

The cardioprotective activity of ALM-802 compound was demonstrated in model experiments simulating postinfarction chronic heart failure in rats forming in 90 days after anterior transmural myocardial infarction. ALM-802 decreased the left ventricle and improved its inotropic function (p=0.038). This effect was observed in case of systematic administration of ALM-802 over 28 days (starting from day 91 after infarction modeling). This is apparently the minimum time for the cardioprotective effect of ALM-802 to prevent or treat the resulting heart failure, because short-term systematic therapy (15 days) produced no positive effect.

Keywords: ALM-802 compound; anterior transmural myocardial infarction; chronic heart failure; experimental therapy terms of 15 days and 28 days; prevention and therapy.

PubMed Disclaimer

References

    1. Barchukov VV, Tsorin IB, Likhosherstov AM, Vititnova MB, Mokrov GV, Gudasheva TA, Kryzhanovskii SA. Anti-Ischemic Activity of Triamine ALM-802 under Conditions of Endothelial Dysfunction. Bull. Exp. Biol. Med. 2019;167(4):460-463. https://doi.org/10.1007/s10517-019-04549-2 - DOI - PubMed
    1. Barchukov VV, Tsorin IB, Likhosherstov AM, Vititnova MB, Mokrov GV, Kryzhanovskii SA. A comparative study of the anti-ischemic activity of trimetazidine and the compound ALM-802 under conditions of endothelial dysfunction. Farmakokinetika Farmakodinamika. 2019;(2):23-27. Russian
    1. Kryzhanovskii SA, Likhosherstov AM, Tsorin IB, Stolyaruk VN, Vititnova MB, Mokrov GV, Gudasheva TA. Screening of the compounds having cardiotropic activity among the α, ω-diarilmetil derivatives of bis-(ω-aminoalkyl) amines. Farmakokinetika Farmakodinamika. 2016;(2):10-13. Russian.
    1. Kryzhanovskii SA, Tsorin IB, Ionova EO, Stolyaruk VN, Vititnova MB, Barchukov VV, Miroshkina IA, Sorokina AV, Kozhevnikova LM, Durnev AD. A translational model of chronic heart failure in rats. Patol. Fiziol. Eksp. Ter. 2018;62(2):136-148. Russian.
    1. Coats CJ, Pavlou M, Watkinson OT, Protonotarios A, Moss L, Hyland R, Rantell K, Pantazis AA, Tome M, McKenna WJ, Frenneaux MP, Omar R, Elliott PM. Effect of trimetazidine dihydrochloride therapy on exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy: a randomized clinical trial. JAMA Cardiol. 2019;4(3):230-235. https://doi.org/10.1001/jamacardio.2018.4847 - DOI - PubMed - PMC

LinkOut - more resources